MedPath

IDDSI Nutritional Drink for Dysphagia Study

Not Applicable
Suspended
Conditions
Malnutrition
Dysphagia
Interventions
Dietary Supplement: IDDSI nutritional supplement drink
Registration Number
NCT03679078
Lead Sponsor
Nutricia UK Ltd
Brief Summary

This study will evaluate the gastrointestinal (GI) tolerance, compliance , acceptability and safety of a ready-to-use oral nutritional supplement drink for patients with dysphagia.

Detailed Description

Dysphagia is a complex condition common in a number of diagnoses including stroke, Parkinson's disease, head and neck cancer, dementia, learning disabilities and gastric/oesophageal motility disorders.

A modified textured diet and/or fluid is considered as an effective intervention in management of dysphagia. The International Dysphagia Diet Standardisation Initiative (IDDSI) have developed a new framework around the terms and descriptors used in the management of individuals with dysphagia. Malnutrition is very common in patients with dysphagia and the use of pre-thickened oral nutritional supplements (ONS) has been found as an effective way to manage this. However, due to impairment in the swallow process, dysphagic patients require pre-thickened oral nutritional supplement to ensure safe consumption of these nutritional supplements.

40 participants, requiring a new pre-thickened oral nutritional supplement in line with the new IDDSI framework recruited from hospitals, outpatients clinics, care homes, community hospitals, community dietetic/speech and language therapy services or stroke rehabilitation units will receive the ready-to-use oral nutritional supplement for a 4 week intervention period. This study aims to primarily evaluate gastro-intestinal tolerance, with secondary outcomes including compliance, acceptability, nutrient intake, anthropometry and safety.

Recruitment & Eligibility

Status
SUSPENDED
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Male or female
  • Age ≥ 18 years
  • Patients with a requirement for ≥ 250kcal/day from a milkshake style ONS for ≥ 4 weeks or current users of ONS
  • Patients identified to require mildly thick (IDDSI level 2) fluids.
  • Patients competent to provide written informed consent and able to answer questions
  • Patients able to take study ONS orally
Exclusion Criteria
  • Patients that lack capacity to provide informed consent
  • Patients that are unable to take study ONS orally
  • Participants with chronic renal disease requiring dialysis
  • Participants with liver failure
  • Participants that are pregnant or lactating
  • Participation in other studies that may interfere with this study
  • Participants receiving 100% total nutritional requirements from tube feeding or parenteral nutrition
  • Patients with galactosaemia or lactose intolerance
  • Patients receiving palliative or end of life care

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
IDDSI nutritional supplement drinkIDDSI nutritional supplement drinkSingle arm designed, 28day on IDDSI nutritional supplement drink
Primary Outcome Measures
NameTimeMethod
Gastrointestinal ToleranceDay 1, Day 2, Day 3, Day 10, Day 17, Day 24 and Day 31

Gastro-intestinal tolerance will be assessed daily throughout a 3 day baseline period before starting the study ONS and at the end of each week (day 10, day 17, day 24, day 31) using a standardised GI tolerance questionnaire including questions on number of bowel movements per day, other gastrointestinal symptoms such as flatulence, bloating, burping and abdominal discomfort. Patient-reported gastrointestinal symptoms with scale range for each symptom as s scale range minimum = none, maximum = severe.

Change of symptom from baseline scale minimum = no change, maximum = worse.

Secondary Outcome Measures
NameTimeMethod
Nutrient intakeDay 1, Day 17 and Day 31

Three dietary recalls relating to the the past 24 hours of Day 1, Day 17 and Day 31 to capture all food and fluids consumed. This will subsequently be analysed in dietary software.

Acceptability: Brief tick-box questionnaireDay 1, Day 17, Day 31

Brief tick-box questionnaire on overall liking and acceptability of product, including texture and feel of nutritional drink, flavor and ease of use. Scale minimum = dislike very much, maximum = like very much Scale minimum = very inconvenient, maximum = very convenient Scale minimum = very difficult, maximum = very easy

ComplianceOnce during baseline period (Day 1) and then daily through intervention period (Days 4-31)

Daily questionnaire on amount of nutritional drink prescribed and amounts actually consumed. Amount of daily ONS actually consumed scale minimum = 0%, maximum = 100%

AnthropometryDay 1 and Day 31

Measurements of height and weight with Body Mass Index (BMI) calculated at baseline and end of study.

Safety (Adverse events reporting)31 days.

Reporting of any adverse events that occur throughout study.

Trial Locations

Locations (8)

Aneurin Bevan University Health Board

🇬🇧

Caerleon, United Kingdom

Dudley Group NHS Trust

🇬🇧

Dudley, United Kingdom

Cambridge University Hospitals NHS Foundation Trust

🇬🇧

Cambridge, United Kingdom

Cwm Taf University Health Board

🇬🇧

Llwynypia, United Kingdom

Croydon Health NHS Trust

🇬🇧

London, United Kingdom

Lewisham and Greenwich NHS Foundation Trust

🇬🇧

London, United Kingdom

Weston Area Health Trust

🇬🇧

Weston-super-Mare, United Kingdom

Great Western Hospitals NHS Foundation Trust

🇬🇧

Swindon, United Kingdom

© Copyright 2025. All Rights Reserved by MedPath